1. Development of Fragment-Based Inhibitors of the Bacterial Deacetylase LpxC with Low Nanomolar Activity.
- Author
-
Mielniczuk S, Hoff K, Baselious F, Li Y, Haupenthal J, Kany AM, Riedner M, Rohde H, Rox K, Hirsch AKH, Krimm I, Sippl W, and Holl R
- Subjects
- Structure-Activity Relationship, Microbial Sensitivity Tests, Molecular Dynamics Simulation, Hydroxamic Acids chemistry, Hydroxamic Acids pharmacology, Hydroxamic Acids metabolism, Hydroxamic Acids chemical synthesis, Humans, Animals, Amidohydrolases antagonists & inhibitors, Amidohydrolases metabolism, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents chemistry, Anti-Bacterial Agents chemical synthesis, Molecular Docking Simulation, Enzyme Inhibitors pharmacology, Enzyme Inhibitors chemistry, Enzyme Inhibitors chemical synthesis
- Abstract
In a fragment-based approach using NMR spectroscopy, benzyloxyacetohydroxamic acid-derived inhibitors of the bacterial deacetylase LpxC bearing a substituent to target the uridine diphosphate-binding site of the enzyme were developed. By appending privileged fragments via a suitable linker, potent LpxC inhibitors with promising antibacterial activities could be obtained, like the one-digit nanomolar LpxC inhibitor ( S )- 13j [ K
i ( Ec LpxC C63A) = 9.5 nM; Ki ( Pa LpxC): 5.6 nM]. To rationalize the observed structure-activity relationships, molecular docking and molecular dynamics studies were performed. Initial in vitro absorption-distribution-metabolism-excretion-toxicity (ADMET) studies of the most potent compounds have paved the way for multiparameter optimization of our newly developed isoserine-based amides.- Published
- 2024
- Full Text
- View/download PDF